Aquestive Therapeutics, Inc. Stock Analysis & AI Score
Aquestive Therapeutics, Inc. (AQST) has an ST Score of 58.7 (B-), driven by its Financial Strength (A+) and held back by its Profitability (D+). Analysts rate it Buy with a $11.00 price target (+128.2% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Aquestive Therapeutics, Inc. (AQST) has an ST Score of 58.7 (B-), driven by its Financial Strength (A+) and held back by its Profitability (D+). Analysts rate it Buy with a $11.00 price target (+128.2% upside).
- Strongest
- Financial StrengthA+
- Weakest
- ProfitabilityD+
All factor grades
- Financial StrengthA+
- ForecastA
- ValuationA-
- MomentumB-
- GrowthC
- ProfitabilityD+
- Piotroski3/9
Contact
AQST stock: frequently asked questions
What is AQST's ST Score?
Aquestive Therapeutics, Inc. (AQST) has an ST Score of 58.7 (B-), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is AQST a buy, hold, or sell?
Analysts rate AQST a Buy, with a price target of $11.00 (+128.2% vs the current price). Our ST Score grades it B- (58.7/100). The ST Score is a data-driven signal, not a recommendation.
What are AQST's factor grades?
Valuation A-, Profitability D+, Financial Strength A+, Momentum B-, Growth C, Forecast A.
What is AQST's valuation grade?
Aquestive Therapeutics, Inc. (AQST) earns a valuation grade of A-, measured against Drug Manufacturers - Specialty & Generic peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is AQST's growth grade?
Aquestive Therapeutics, Inc. (AQST) earns a growth grade of C, measured against Drug Manufacturers - Specialty & Generic peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is AQST's profitability grade?
Aquestive Therapeutics, Inc. (AQST) earns a profitability grade of D+, measured against Drug Manufacturers - Specialty & Generic peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is AQST's financial strength grade?
Aquestive Therapeutics, Inc. (AQST) earns a financial strength grade of A+, measured against Drug Manufacturers - Specialty & Generic peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for AQST?
The average analyst price target for Aquestive Therapeutics, Inc. (AQST) is $11.00 from 10 analysts, which is +128.2% versus the recent price of $4.82.
What is AQST's Piotroski score?
Aquestive Therapeutics, Inc. (AQST) has a Piotroski F-Score of 3 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.